FLT3 inhibitor (tyrosine kinase inhibitor) and B-cell lymphoma-2 inhibitor coordinate and eliminate FLT3/ITD mutations of acute leukemia cells via B-cell lymphoma 2-like protein 11 activations53. The gene discussed is FLT3; the disease is acute leukemia.